Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Dermatologic 1CNS 1

Conditions

Uveal Melanoma 1Sarcoma 1Osteosarcoma 1Neuroblastoma 1Myelodysplastic Syndromes 1Melanoma 1Leukemia, Myeloid, Acute 1

Interventions

Cyclophosphamide 7Flow Cytometry 4fludarabine 3Therapeutics 3Polymerase Chain Reaction 3Nivolumab 3liposomal amphotericin B 2aldesleukin 2Voriconazole 2Psychiatric Rehabilitation 2Ondansetron 2Melphalan 2Itraconazole 2Ipilimumab 2Immunologic Techniques 2Etoposide 2Dexamethasone 2Caspofungin 2Carboplatin 2Calcium Dobesilate 2Busulfan 2Aprepitant 2Amplified Fragment Length Polymorphism Analysis 2Alemtuzumab 2tipifarnib 1sargramostim 1pembrolizumab 1lorukafusp alfa 1humanized 3F8 anti-GD2 monoclonal antibody 1fludarabine phosphate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroblastoma × AP 1903 reagent × Dermatologic × Clear all
NCT02107963 2024-05-16

A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
15 enrolled
CNSDermatologicSarcoma

Melanoma, Neuroblastoma, Sarcoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡